Cell Death Differ:研究表明鱼油成分有助于受损大脑和视网膜细胞的存活

2017-04-22 MedSci MedSci原创

由新奥尔良医学院LSU健康神经科学中心主任兼教授Nicolas Bazan博士领导的研究团队首次表明,由DHA制造的信号分子NDP1可以激发在大脑和视网膜中产生的一种抗有毒自由基和脑、视网膜损伤的保护性蛋白质的生成。在缺血性卒中和人视网膜色素上皮(RPE)细胞的实验模型中进行的研究,研究成果发表在Nature的Cell Death and Differentiation上。

由新奥尔良医学院LSU健康神经科学中心主任兼教授Nicolas Bazan博士领导的研究团队首次表明,由DHA制造的信号分子NDP1可以激发在大脑和视网膜中产生的一种抗有毒自由基和脑、视网膜损伤的保护性蛋白质的生成。在缺血性卒中和人视网膜色素上皮(RPE)细胞的实验模型中进行的研究,研究成果发表在Nature的Cell Death and Differentiation上。

神经保护素D1(NPD1)是ω-3脂肪酸二十二碳六烯酸(DHA)合成的维持细胞存活的脂质信使。NPD1于2004年由Bazan博士及其同事发现并命名。由于不断产生有害自由基导致的氧化应激,为细胞死亡奠定了基础。由于灾难性事件,如缺血性卒中,以及神经变性和致盲性疾病,细胞死亡加速。研究小组发现,NPD1在两个小时的实验性卒中后一小时内系统给药,增加了环指蛋白146的产生和获得,这被称为Iduna。

Iduna促进DNA修复,通过抑制PARP的破坏性蛋白质的产生来防止中风中被称为parthanatos的程序性细胞死亡。研究人员发现NDP1对Iduna活性的影响在氧化应激发作后6小时达到峰值,剂量依赖性曲线显示NPD1达25nM时,Iduna活性在两种类型的人类RPE细胞中均增加。这些结果表明,当未补偿的氧化应激触发NPD1的形成时,NDP1选择性诱导Iduna活性,从而激活Iduna。

"这些发现意义重大,因为它们显示了NPD1,一种脂质调解剂'按需要' 调节了一种对细胞存活至关重要的蛋白质(Iduna)的丰度。" 新奥尔良医学院LSU健康神经科学中心的教授和主任Nicolas Bazan博士说道。"这种蛋白质,研究得相对较少,被证明是细胞功能重新编程和生存的关键。" 在鱼油中发现的DHA是必需的ω-3脂肪酸,对于正常的大脑功能至关重要。这也是神经系统发育所必需的,包括视觉。2011年Bazan实验室发表的一项研究发现,DHA引发了神经保护素D1的产生,神经保护素D1是来自DHA的脑中天然存在的神经保护分子。NDP1生物活性控制关键基因相互作用在疾病或损伤威胁时对细胞存活有决定性作用。

"DHA-NPD1-Iduna表达信号的分子细节的进一步揭开可能有助于视网膜退化和缺血性卒中的治疗干预。 Bazan说。

原文出处

Ludmila Belayev et al. Neuroprotectin D1 upregulates Iduna expression and provides protection in cellular uncompensated oxidative stress and in experimental ischemic stroke, Cell Death and Differentiation (2017).

此文系梅斯医学(MedSci)原创编译整理,转载须授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1784204, encodeId=bcd51e84204e7, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Sat Dec 30 10:52:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960176, encodeId=21d919601e60a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Jan 22 00:52:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869917, encodeId=3e3d186991e2e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat May 27 19:52:00 CST 2017, time=2017-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269866, encodeId=7ed1126986617, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon Apr 24 01:52:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531404, encodeId=548b153140444, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Mon Apr 24 01:52:00 CST 2017, time=2017-04-24, status=1, ipAttribution=)]
    2017-12-30 isabellayj
  2. [GetPortalCommentsPageByObjectIdResponse(id=1784204, encodeId=bcd51e84204e7, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Sat Dec 30 10:52:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960176, encodeId=21d919601e60a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Jan 22 00:52:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869917, encodeId=3e3d186991e2e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat May 27 19:52:00 CST 2017, time=2017-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269866, encodeId=7ed1126986617, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon Apr 24 01:52:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531404, encodeId=548b153140444, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Mon Apr 24 01:52:00 CST 2017, time=2017-04-24, status=1, ipAttribution=)]
    2018-01-22 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1784204, encodeId=bcd51e84204e7, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Sat Dec 30 10:52:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960176, encodeId=21d919601e60a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Jan 22 00:52:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869917, encodeId=3e3d186991e2e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat May 27 19:52:00 CST 2017, time=2017-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269866, encodeId=7ed1126986617, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon Apr 24 01:52:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531404, encodeId=548b153140444, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Mon Apr 24 01:52:00 CST 2017, time=2017-04-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1784204, encodeId=bcd51e84204e7, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Sat Dec 30 10:52:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960176, encodeId=21d919601e60a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Jan 22 00:52:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869917, encodeId=3e3d186991e2e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat May 27 19:52:00 CST 2017, time=2017-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269866, encodeId=7ed1126986617, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon Apr 24 01:52:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531404, encodeId=548b153140444, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Mon Apr 24 01:52:00 CST 2017, time=2017-04-24, status=1, ipAttribution=)]
    2017-04-24 zutt
  5. [GetPortalCommentsPageByObjectIdResponse(id=1784204, encodeId=bcd51e84204e7, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Sat Dec 30 10:52:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960176, encodeId=21d919601e60a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Jan 22 00:52:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869917, encodeId=3e3d186991e2e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat May 27 19:52:00 CST 2017, time=2017-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269866, encodeId=7ed1126986617, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon Apr 24 01:52:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531404, encodeId=548b153140444, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Mon Apr 24 01:52:00 CST 2017, time=2017-04-24, status=1, ipAttribution=)]
    2017-04-24 cy0328

相关资讯

NEJM:孕妇吃深海鱼油能预防后代哮喘

研究者评估了补充n-3 长链多不饱和脂肪酸(LCPUFA),俗称深海渔油的保护作用。在孕妇中补充鱼油能否减少下一代的持续喘息和哮喘的风险。研究者采用随机对照研究方法,在妊娠24周时随机分配736名孕妇,每天接受2.4克n-3 LCPUFA(鱼油)或安慰剂(橄榄油)进行对比。这些人此前属于哥本哈根儿童哮喘哮喘前瞻性研究(COPSAC2010)队列。主要终点是持续喘息或哮喘,次要终点包括下呼吸道感染,

多项研究表明:多吃鱼油有利身体健康

多项研究表明:多吃鱼油有利身体健康越来越多的研究证明,鱼油对身体健康的价值。鱼油不仅可以减轻体重、提高生育力、改善皮肤健康和增加能量,而且还能逆转高脂肪饮食带来的有害代谢,降低冠心病发病风险,治疗膝骨关节炎等作用。近日,一项新研究表明,鱼油补充剂可逆转高脂肪饮食带来的有害代谢作用,如2型糖尿病,相关研究结果于近日发表在《Journal of Physiology》杂志上。在这项新研究中,巴西圣

吃鱼油好处多多 你知道吗?

我们都知道鱼油中富含ω-3系多不饱和脂肪酸(DHA和EPA),其具有抗炎、调节血脂等多种健康益处。近年来科学家也通过大量研究发现了鱼油的其它好处,比如鱼油能够降低个体患癌症的风险,而且吃鱼油还能够降低个体患心血管疾病的风险,那么鱼油还有哪些健康益处呢?本文中小编就对此进行了盘点,与各位一起学习! 【1】JCI Insight & NEJM:两篇重磅级文章证实鱼油可有效治疗哮喘症

JAMA Intern Med:动静脉内瘘术患者服用鱼油或阿司匹林,受益甚微

血管通路功能障碍是血液透析患者发病和死亡的主要原因。由于卓越的长期结果和较低的医疗费用,动静脉瘘优于人工移植物和中央静脉导管,但它们的使用易造成早期的血栓形成和成熟不良。ω- 3多不饱和脂肪酸(鱼油)在血管生物学和炎症的多效性作用与阿司匹林的抗血小板聚集功效或可降低失败风险。1月,JAMA Intern Med上发表的一项研究探究了鱼油补充剂(主要目标)和阿司匹林(次要目标)的使用对动静脉内瘘术的

NEJM:孕妇为何要服用鱼油?给了你一个新理由

孕妇是否应该服用鱼油?网上关于孕妇与鱼油的帖子很多,有些持负面态度的,也有持正面态度的。近日,丹麦的研究人员发现,在孕期24周后服用鱼油补充剂可以降低后代患持续性喘息或哮喘的风险。12月29日,《新英格兰医学杂志》上的一项新研究表明,女性在孕期后三个月服用鱼油补充剂可以减少后代持续性喘息或哮喘以及下呼吸道感染的风险,这项研究有助于预防日益严重的儿童哮喘问题。哮喘在发达国家越来越普遍。早期研究表明,

J Allergy Clin Immunol:孕期补充鱼油可影响后代过敏性呼吸系统疾病的发生?

作为营养保健品,鱼油得到了许多消费者的青睐。2017年1月,发表在《J Allergy Clin Immunol》的一项由丹麦和美国科学家进行的研究考察了孕期补充鱼油对后代过敏性呼吸系统疾病的作用。